ERBB2 and breast carcinoma: Specifically, the immunohistochemical analysis of estrogen receptors (ER), progesterone receptors (PR), and the human epidermal growth factor receptor 2 (HER2) remains the standard procedure to stratify breast cancer patients [3,4].